Journal of Medicinal Chemistry · 2018 · 48 citations · 21 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryStructure-activity RelationshipsLigand BindingLigand-based DesignMolecular DockingPotency OptimizationStructure-activity Relationship AnalysisKinase Inhibitor Library DesignMolecular Docking Of InhibitorsStructure-based Ligand DesignTumor Metastasis Biology
We herein report the structural optimization and structure–activity relationship studies of 5-(2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as a new class of receptor-interacting protein kinase 1 (RIPK1) inhibitors. Among all obtained RIPK1 inhibitors, 1-(5-{4-amino-7-ethyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2,3-dihydro-1H-indol-1-yl)-2-[3-(trifluoromethoxy)phenyl]ethan-1-one (22b) is the most active one. This compound potently inhibited RIPK1 with a binding affinity (KD) of 0.004 μM and an enzymatic IC50 value of 0.011 μM and also showed good kinase selectivity. It could efficiently protect cells from necroptosis and attenuate the necrotic cell death of vascular endothelial cells induced by tumor cells both in vitro and in vivo. Importantly, compound 22b exhibited excellent antimetastasis activity in the experimental B16 melanoma lung metastasis model. It also displayed favorable pharmacokinetic properties. Collectively, 22b could be a promising agent for preventing tumor metastasis.
21
Clinical development success rates for investigational drugs
Michael Hay, David W. Thomas, John L. Craighead et al. · Nature Biotechnology · 2014 · 2.5K citations
Tumour-cell-induced endothelial cell necroptosis via death receptor 6 promotes metastasis
Boris Strilić, Lida Yang, Julián Albarrán-Juárez et al. · Nature · 2016 · 567 citations